Clin2
NCT04695106Possibly a fitRecruiting

Blood Thinner and Heart Attack Prevention Study

Atrial FibrillationAntithrombotic TherapyAcute Coronary SyndromePercutaneous Coronary Interventions

Treatments studied

Part of Heart & circulation clinical trials.

This study tests whether taking dabigatran (a blood thinner) combined with ticagrelor (a blood clot preventer) is safe and effective for patients with irregular heart rhythm (atrial fibrillation) who recently had a heart attack and received a stent. The goal is to prevent future blood clots while minimizing bleeding risks.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
1,194 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You had a recent heart attack (within the last 120 hours) and received a stent to open a blocked artery
  • You have atrial fibrillation (irregular heartbeat) and are either already taking or willing to start dabigatran
  • You have no serious kidney, liver, or bleeding problems
  • You have not had major surgery, stroke, or significant bleeding in the past month
  • You are willing to take two blood-thinning medications and avoid certain drug interactions

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04436978Recruiting· Phase 4
Best blood thinner plan for atrial fibrillation after stent

This study compares different blood-thinner (“antithrombotic”) strategies in people with atrial fibrillation or flutter who recently had a stent placed (PCI). It aims to find a plan that lowers clot risk while keeping bleeding risk as low as possible.

Aalst
NCT04240834Recruiting· Phase 4
Low-dose ticagrelor vs aspirin after heart stent placement

This study compares ticagrelor taken at a lower dose versus regular aspirin to help prevent future heart attacks in people who recently had a stent placed after acute coronary syndrome. You may qualify if you’re considered “high risk” for new blockages or clots and can take dual anti-platelet therapy for 12 months.

Beijing, Beijing Municipality
NCT04937699Recruiting· Phase 4
Switching anti-platelet tablets after a heart stent

This trial studies whether changing the timing and type of blood-thinner tablets after a heart stent is as safe and effective as continuing the same plan. It may help some people by simplifying treatment while preventing dangerous clotting after a coronary procedure.

Hangzhou, Zhejiang
NCT07582835Recruiting· Phase 3
Long-term heart clot prevention after stent placement

This study tests whether taking a single blood-thinning medication (instead of two) after heart stent placement is safe and effective over the long term. If you've recovered well from a stent procedure, this trial may help determine the safest way to prevent future heart problems.

Lugano, Ch/ti
NCT07583784Not yet recruiting
Shorter blood thinner treatment after heart attack with irregular heartbeat

This trial tests whether patients with both irregular heartbeat (atrial fibrillation) and a recent heart attack can safely take a shorter course of blood-thinning medications after a stent procedure. The goal is to reduce bleeding risk while still protecting against future clots.

Gwangju, Gwangju
NCT07626411Recruiting· Phase 3
Blood Thinner Study for Irregular Heartbeat

This study tests a new blood thinner to prevent strokes and blood clots in people with atrial fibrillation (a common heart rhythm problem). You may qualify if you have atrial fibrillation and at least one risk factor for stroke, or if you've never taken a blood thinner before.

Dothan, Alabama

Hear when a new Atrial fibrillation trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.